北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 病理科  > 期刊论文
学科主题: 临床医学
题名:
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma
作者: Ding, Ning1; Li, Xitao2; Shi, Yunfei3; Ping, Lingyan1; Wu, Lina4; Fu, Kai5; Feng, Lixia1; Zheng, Xiaohui1; Song, Yuqin1; Pan, Zhengying2; Zhu, Jun1
关键词: BCR signaling ; Btk ; irreversible inhibitor ; targeted therapy ; B-cell lymphoma
刊名: ONCOTARGET
发表日期: 2015-06-20
卷: 6, 期:17, 页:15122-15136
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Cell Biology
研究领域[WOS]: Oncology ; Cell Biology
关键词[WOS]: CHRONIC LYMPHOCYTIC-LEUKEMIA ; TYROSINE KINASE INHIBITOR ; IN-VIVO ; THERAPEUTIC TARGET ; RECEPTOR ; PCI-32765 ; IBRUTINIB ; PATHWAY ; MALIGNANCIES ; ACTIVATION
英文摘要:

The B-cell receptor (BCR) signaling pathway has gained significant attention as a therapeutic target in B-cell malignancies. Recently, several drugs that target the BCR signaling pathway, especially the Btk inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory patients, which indicates that pharmacological inhibition of BCR pathway holds promise in B-cell lymphoma treatment. Here we present a novel covalent irreversible Btk inhibitor PLS-123 with more potent anti-proliferative activity compared with ibrutinib in multiple cellular and in vivo models through effective apoptosis induction and dual-action inhibitory mode of Btk activation. The phosphorylation of BCR downstream activating AKT/mTOR and MAPK signal pathways was also more significantly reduced after treatment with PLS-123 than ibrutinib. Gene expression profile analysis further suggested that the different selectivity profile of PLS-123 led to significant downregulation of oncogenic gene PTPN11 expression, which might also offer new opportunities beyond what ibrutinib has achieved. In addition, PLS-123 dose-dependently attenuated BCR- and chemokine-mediated lymphoma cell adhesion and migration. Taken together, Btk inhibitor PLS-123 suggested a new direction to pharmacologically modulate Btk function and develop novel therapeutic drug for B-cell lymphoma treatment.

语种: 英语
所属项目编号: 81470368 ; 81201873 ; 2013CB910704 ; 2011CB504303 ; 7132050 ; JCYJ20140509093817688 ; 81373270
项目资助者: NSFC ; 973 program ; Beijing Natural Science Foundation ; Shenzhen Science and Technology Innovation Committee ; National Natural Science Foundation of China ; "985" Basic Research Fund from Peking University
WOS记录号: WOS:000359010700037
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/64721
Appears in Collections:北京大学临床肿瘤学院_病理科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ,Dept Lymphoma, Beijing 100871, Peoples R China
2.Peking Univ, Shenzhen Grad Sch, Sch Chem Biol & Biotechnol, Key Lab Chem Genom, Shenzhen, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China
4.Peking Univ, Canc Hosp & Inst, Cent Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China
5.Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA

Recommended Citation:
Ding, Ning,Li, Xitao,Shi, Yunfei,et al. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma[J]. ONCOTARGET,2015,6(17):15122-15136.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Ding, Ning]'s Articles
[Li, Xitao]'s Articles
[Shi, Yunfei]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Ding, Ning]‘s Articles
[Li, Xitao]‘s Articles
[Shi, Yunfei]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace